PLoS ONE (Jan 2019)

Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry.

  • Jindrich Spinar,
  • Lenka Spinarova,
  • Filip Malek,
  • Ondrej Ludka,
  • Jan Krejci,
  • Petr Ostadal,
  • Dagmar Vondrakova,
  • Karel Labr,
  • Monika Spinarova,
  • Monika Pavkova Goldbergova,
  • Klara Benesova,
  • Jiri Jarkovsky,
  • Jiri Parenica

DOI
https://doi.org/10.1371/journal.pone.0214363
Journal volume & issue
Vol. 14, no. 3
p. e0214363

Abstract

Read online

BACKGROUND:According to guidelines, the prognosis of patients with chronic heart failure can be predicted by determining the levels of natriuretic peptides, the NYHA classification and comorbidities. The aim our work was to develop a prognostic score in chronic heart failure patients that would take account of patients' comorbidities, NYHA and NT-proBNP levels. METHODS AND RESULTS:A total of 1,088 patients with chronic heart failure with reduced ejection fraction (HFrEF) (LVEF1000 ng/L respectively. Discrimination abilities of NYHA and NT-proBNP were AUC 0.670 (p40 mg daily) (AUC 0.773; p<0.001) was increased by adding the NT-proBNP level (AUC 0.790). CONCLUSION:The use of prediction models in patients with chronic heart failure, namely those taking account of natriuretic peptides, should become a standard in routine clinical practice. It might contribute to a better identification of a high-risk group of patients in which more intense treatment needs to be considered, such as heart transplantation or LVAD implantation.